AstraZeneca’s response to the COVID-19 (novel coronavirus) outbreak is consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.
Our medicines supply chain is robust, and we continue to monitor the situation closely. Our stringent quality management system ensures the safety, quality and efficacy of all our medicines at all times. In the UK, we are confident that we have sufficient product to maintain availability to patients.
To help protect the health and wellbeing of our 8,300 employees in the UK and the communities in which we operate, we have implemented temporary measures to help reduce the risk of infection. Unless they play a critical role in the COVID-19 response or are involved in the manufacture and distribution of essential medicines, AstraZeneca employees are now working from home wherever possible. Where employees are required to be onsite, all precautions set out by Public Health England have been implemented.
AstraZeneca’s Research and Development (R&D) teams have been working expeditiously to identify monoclonal antibodies to progress towards clinical trial evaluation as a treatment to prevent COVID-19. More than 50 virology, immunology, respiratory, and protein engineering experts across research, clinical, regulatory, and manufacturing are placing the highest priority on developing a treatment to minimise the global impact of the disease.
Further information about our global efforts against COVID-19 is available on our global website here.
How is AstraZeneca supporting the COVID-19 response in the UK?
As the UK’s leading global biopharmaceutical company and investor in life sciences, we are working closely with the UK Government and the NHS to support the national response to the COVID-19 pandemic in every way that we can.
We are enabling trained medical and nursing staff from AstraZeneca to volunteer for the NHS, and are leveraging our extensive global presence to secure vital supplies, including personal protective equipment (PPE) and other laboratory equipment and materials that are required urgently.
We are also leveraging our expertise in the areas of cancer, respiratory disease and cardio-renal-metabolic disease, to help the NHS ensure continuity of care for vulnerable patients. So far, this work includes:
- Enabling the delivery and administration of critical medicines to at-risk patients in the relative safety of their home
- Providing education and facilitating best practice sharing for healthcare professionals on the optimal management of patients during the COVID-19 outbreak
- Supporting charities in their work to guide patients during this uncertain time.
Working together, we can meet the unprecedented challenge of COVID-19.
For further information:
Supply chain: email@example.com
All other enquiries: Medical.informationUK@astrazeneca.com
VVPM ID: GB-21170 Date of prep: April 2020